Sentences with phrase «other disease therapies»
It has a critical role in regulating cell proliferation, so understanding ERK regulation is central to efforts to design new cancer drugs and other disease therapies.
https://www.pnnl.gov/ Not exact matches
Why have we made more progress on certain diseases while other mass - scale killers, like chronic obstructive pulmonary disease (COPD), are largely off of people's radars and so difficult to treat in an age of therapies which can resemble magic?
About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.
«There's already fantastic therapies to overcome heart disease, cancer and every other neurological disease based on this idea of reprogramming the software,» Kurzweil said.
Minoryx is a clinical stage biotech company leading the development of new therapies for X-linked Adrenoleukodystrophy (X-ALD) and other inborn errors of metabolism, a group of rare diseases of genetic origin with a high unmet medical need.
That therapy for treating melanoma is already in the development pipeline, along with 906 other biologics targeting over 100 diseases from autoimmune disorders to viruses.
a. free from any infection or other form of disease or malformation, or from experimental therapy or manipulation.
Compression socks are specialized bandages or garments used in compression therapy for the management of lymphedema, chronic venous disease or other blood pressure related conditions.
Findings could trigger new therapies for cerebral palsy, multiple sclerosis and other debilitating diseases, including the subject of the feature film Lorenzo's Oil
«As a consequence, and assuming that others can replicate our findings, that could lead to therapies, ways of prevention, and ways of anticipating disease that don't now exist.»
It could also lead to the development of new therapies against other more common neurodegenerative disorders of the central nervous system, as well as diseases related to the propagation of pathological proteins, including Parkinson's and Alzheimer's.
What's more, the researchers who made the discovery say their finding will aid in the design of therapies for thyroid problems, such as Graves» disease, and problems with other glands that operate in a similar fashion.
The WHI hormone therapy trials assessed heart disease, breast cancer, stroke, blood clots, colorectal cancer, hip fractures and deaths from other causes in women who used the hormones versus those who took a placebo.
The trial, part of a multifaceted project called the Women's Health Initiative, or WHI, was meant to examine hormone therapy's effectiveness in lowering the risk of heart disease and other conditions in women ages 50 to 79.
Using «freshman physics,» neuroscientists have deployed electric fields to stimulate neurons buried deep in the brains of mice — a method that could one day lead to noninvasive therapies for people with Parkinson's disease and other brain disorders.
The biological complexity of cancer and other diseases demands a more formidable arsenal of therapies than currently available.
«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.
Because cGVHD has a similar pathophysiology to some autoimmune diseases, it is likely that these findings will be useful for developing new treatments and preventive therapies in other conditions.
The researchers believe there are other disease entities, aside from cancers, that may be significantly affected by targeted epigenetic therapies.
«It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune - mediated diseases as well as other epigenetically - influenced diseases,» said Alani, who also is chief of dermatology at Boston Medical Center.
Researchers at the 12th International Neuroscience Winter Conference will explore, among other hot topics in neuroscience, the neurobiology of courtship, new gene therapy approaches in Parkinson's disease, the role of sleep in neuropsychiatric disorders and breakthroughs in brain repair.
Patients who got it lived about 4 months longer, nearly 26 months total, than those who didn't — but that, say company executives, is still more than any other therapy has managed for this disease in a randomized trial.
Last year the National Institutes of Health announced plans to put some 180 ex-Coulston chimps currently housed at the Alamogordo Primate Facility back in service, to rejoin the roughly 800 other chimps that serve as subjects for studies of human diseases, therapies and vaccines in the U.S., which is the only country apart from Gabon to maintain chimps for this purpose.
Neuroscientists are optimistic that the success of nusinersen may portend similar positive results for antisense therapies now being developed to fight other genetically linked nervous system diseases like amyotrophic lateral sclerosis and Huntington disease.
«If we could do this in one disease, it's a good bet the therapy would be effective in the other two diseases.»
These observations and others have convinced the researchers that their CRISPR / Cas9 and hPSC system produces a stable, biologically accurate human model for a common genetic disease where new understanding and new therapies are desperately needed.
siRNAi therapy could also work against other liver diseases, says molecular geneticist John Rossi of City of Hope in Duarte, California.
The study results show that with a median (midpoint) follow - up of 20 months, 232 patients (75 percent) remained on therapy, 31 (10 percent) discontinued because of disease progression and 45 discontinued for other reasons (including 28 because of infection, eight for other adverse events and nine due to other medical events).
An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.
«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.
AAV1 is considered safe as a viral vector and is already in use in human gene therapy trials for blindness, heart disease, muscular dystrophy and other conditions.
«If, as we postulate, the combination of chemotherapy and PARP inhibition is successful in treating patients with HRD tumors, I expect that others will start exploring whether similar drugs or analogous therapies can make a difference in these diseases,» Heeke concludes.
Prof. Schuelke emphasizes: «Our results are a good example of how the study of rare genetic diseases can provide insights into general disease mechanisms, which may also play a role in other conditions, such as paraplegia, and which may give rise to the development of regenerative therapies.»
Italy is already beginning to show its promise with the development of gene - therapy techniques and the discovery of genes that could lead to a cure for Parkinson's disease and other neurodegenerative disorders.
The findings also point to the potential for new therapies for lupus and other autoimmune disease based on inhibiting the action of EBNA2 or other human proteins that bind to DNA at the same loci along with the viral protein, the researchers say.
«We were surprised to find so many similarities between these two diseases, but most striking was that some of these common signatures are shared with other conditions like diabetic retinopathy and age - related macular degeneration,» said William A. Beltran, senior author on the study, an associate professor of ophthalmology in Penn Vet's Department of Clinical Sciences and Advanced Medicine and director of the Division of Experimental Retinal Therapies.
While the disease can take many forms, recent advances have better characterized how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches.
The method, reported in the November issue of Nature Biotechnology, could lead to safe and effective human gene therapies for cystic fibrosis, hemophilia, and a variety of other diseases.
This could lead to novel therapies to help patients with MS and many other diseases associated with myelin.
Enzalutamide, which is taken as four pills once per day, is already approved by the Food and Drug Administration (FDA) for men whose disease has not been stopped by other treatments including, surgery, radiation, androgen deprivation therapy and chemotherapy.
A new class of therapies may be on the horizon for thyroid eye disease (TED) and other destructive scarring conditions.
However, the researchers believe that these results are proof of concept that gene therapy is a valid strategy against aplastic anemia; this therapy could also be applied to other genes — besides from telomerase — if a causal role for those other forms of the disease was discovered.
The test, described in tomorrow's issue of the journal Circulation, might be used to devise better antioxidant vitamin therapies against free radicals and to explore the mechanism of these compounds in cancer and other diseases.
Keeping the faith Even when all the kinks are addressed, stem cell therapies may heal some patients but not others with the same disease.
This may contribute to the development of stem cell therapy targeted at other diseases.
The discovery could lead to targeted therapies and interventions for Alzheimer's disease, autism and other neurological conditions.
In the coming years, we're working hard to bring new therapies to market for patients with MS, amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease), hemophilia, and others.
Thus, finding new targets for drugs already in use to treat other diseases, in other words drug repurposing, is an emerging area in developing anti-cancer therapies.
The team envisions that in the future, deaf people might benefit from gene therapy similar to the approaches currently being tested in clinical trials for other diseases.
A handful of other companies are also in the field, working on therapies that treat diseases of the central nervous system or enhance cancer immunotherapy.